Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 Tablets
← catalyst calendarNCT05618028 · readout ≤ 1,077 d
Sponsored by AbbVie (industry) · ABBV — their whole pipeline →.
Phase
Phase 1
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
78actual
Sites
39
Countries
Australia, Belgium, France +7
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-04-04 | actual | When the study began enrolling |
| Primary completion | Jul 2029 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Jul 2029 | estimated | The whole study's end, after follow-up |
| First posted | 2022-11-16 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-05-04 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Diffuse Large B-Cell Lymphoma
- Chronic Lymphocytic Leukemia
- B Cell Malignancies
- Non-Hodgkin's Lymphoma
Intervention
- Drug: ABBV-525
Primary outcomes
what the primary-completion date above is the date OFNumber of Participants With Adverse Events (AE)
measured Up to Approximately 64 Months
Number of Participants With Dose-Limiting Toxicities (DLT)
measured Up to Approximately 28 Days
Number of Tumor Lysis Syndrome (TLS)
measured Up to Approximately 64 Months
Number of Participants With Clinically Significant Changes From Baseline in Clinical Laboratory Parameters
measured Up to Approximately 64 Months
Number of Participants With Clinically Significant Changes From Baseline in Vital Sign Parameters
measured Up to Approximately 64 Months
Number of Participants With Clinically Significant Changes From Baseline in Electrocardiograms (ECG)
measured Up to Approximately 64 Months
Maximum Observed Plasma Concentration (Cmax) of ABBV-525
measured Up to 12 Months
Time to Cmax (Tmax) of ABBV-525
measured Up to 12 Months
Area Under the Plasma Concentration-Time Curve (AUC) of ABBV-525
measured Up to 12 Months
Permalink · ABBV's whole pipeline · Catalyst calendar · Every registered study · What changed